The NCCN update also reflects the growing role of CSF-based molecular testing across CNS cancers, including expanded recommendations in certain biopsy-infeasible high-grade gliomas and glioblastoma settings.
Weekly updates from the National Comprehensive Cancer Network share every time a change is made to evidence-based, expert consensus-driven guidelines for cancer prevention, screening, treatment, and supportive care ....
IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia will present two posters highlighting how its tests provide insights into treatment response and aid therapeutic decision-making for EBC... .
"Following the recent NCCN Guidelines update recognizing MammaPrint as the only genomic test to personalize the use of anthracycline-based regimens in HR+HER2- early-stage breast cancer, the data ...